Smithsonian magazine quoted Michael W. Russell, PhD, professor emeritus of microbiology and immunology
, for a story on the potential effectiveness of an intranasal COVID-19 vaccine. Early data is promising, but a marketable vaccine is still at least a year from becoming a reality. “For real control of the pandemic, what we want to do is not just prevent serious disease and death — as good as that is in itself — but we want to be able to break the chains of transmission,” Russell said. If such a vaccine existed, it would travel through the upper respiratory tract, encouraging the body to produce protective antibodies there. If successful, this immune response would both neutralize the virus on its way in before making a person sick, and ensure that no live virus escapes when they exhale, cough or sneeze.